Cancer Research and Biotechnology AG (CRB) is a Swiss biopharma company developing a novel small molecule treatments effective in pancreatic c., triple-negative breast c., and colon cancer. CRB091 is non-toxic, targeting triple-negative breast cancer (TNBC). First in-human submission in 2025.
Products, services, technology
CRB091, oncology, late preclinical. The CRB team has identified a root cause or amplifier of many human cancers. This constitutes the first step towards a safer effective curative and protective method to treat cancer patients. Pancreatic cancer, triple-negative breast cancer, and colon cancer.
Cooperation possibilities
Funding: Non-toxic cancer drugs on fast-to-market regulatory pathway. Shown effective against deadly cancers with high unmet medical need, TNBC, CRC, and PC. Next, first in-human studies on a fast track.
Research: Therapeutic agents affecting the mitochondrial metabolic pathways.
Out-licensing: TNBC
- http://www.crab.ch
- +41 79 616 26 94
- kari@crab.ch
- Kari Sarvanto
Some insights
Developing non-toxic cancer treatments for advanced deadly cancers with no cure today.
Invented and patented a well-tolerated treatment to reverse carcinogenesis, aiming to bring it to the patients in record-short time.
Surgeons and nurses and others working with the cancer patients daily
Novel cancer drugs with no adverse effects, effective against deadly cancers. Platform innovation to treat cancer, neurodegeneration, other degenerative diseases - first drug against the root cause of deadly cancers.
Investors, private and institutional, pharma partners, medical and clinical professionals.
